Mitchell Dowsett, PhD, of the Royal Marsden Hospital discusses the EndoPredict test, which has improved performance compared with the widely used Oncotype Dx test (Abstract S3-01).
Jame Abraham, MD, of the Cleveland Clinic, discusses the 10-year follow-up of this trial, and the long-term benefit and safety of adding trastuzumab to the adjuvant treatment of HER2-positive early breast cancer (Abstract S5-04).
Sherene Loi, MD, of Peter MacCallum Cancer Centre, discusses a pooled individual patient data analysis of stromal tumor-infiltrating lymphocytes in primary triple-negative breast cancer treated with anthracycline-based chemotherapy (Abstract S1-03).
Judy E. Garber, MD, MPH, of the Dana-Farber Cancer Institute, gives her expert perspective on this vital and timely topic.
Matthew J. Ellis, PhD, FRCP, of the Baylor College of Medicine, gives his expert perspective on this evolving area of research.
Patricia A. Ganz, MD, of the University of California at Los Angeles, discusses this clinical trial of anastrozole vs tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (Abstract S6-04).
